It seems that there is still a cultural conflict between organizations in the UK and the US. A US pharmaceutical company, Relmada by name, is angry at the deceptive practices of a powerful UK bank, Laidlaw & Company. Laidlaw has been accused in US Federal Court of manipulating Relmada by attempting to buy them out after both had a scuffle over the handling of Relmada’s financial information.
Relmada is trying to develop a new product, BuTab, but this financial scuffle is slowing down that process. The bad attention that the lawsuit is bringing on both of them is regrettable. Relmada is hoping that justice will be served, and the overly competitive practices of Laidlaw will be brought to a head, so that Relmada can continue with innovation.
Entry level employees of Laidlaw complain on Glassdoor about bad working conditions, with long phone calls, and customers causing stress.
Relmada’s CEO reported satisfaction with this outcome. Sergio Traversa was upset at the conflict, and concluded, “We are pleased that the Court recognized the merits of our request.”